beta-Caryophyllene alcohol is an oxygenated caryophyllane sesquiterpene better known in reference databases and fragrance-safety literature than in direct human research. In the AromaForge archive it currently appears as a minor hinoki wood constituent, while public chemistry sources also list occurrence in foods, spices, and fragrance materials. The strongest source-backed evidence for the isolated compound in this pass is identity data, one animal pharmacokinetic paper, and fragrance-safety review coverage rather than robust constituent-specific efficacy studies.
Chemical identity and composition
PubChem resolves beta-caryophyllene alcohol as CID 61125 with formula C15H26O and the simple tricyclic alcohol name 4,4,8-trimethyltricyclo[6.3.1.0(2,5)]dodecan-1-ol. PubChem synonyms include Caryolan-1-ol and CAS 472-97-9. In the local archive it is already recorded in hinoki wood oil at 1.49% based on a public GC analysis transcription.
Aroma and practical use
- Use the recorded woody, spicy, mossy descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2018 rat and beagle-dog pharmacokinetic study reported short elimination half-lives, high systemic clearance, and very low oral bioavailability for beta-caryophyllene alcohol across the tested formulations.
A 2018 rat and beagle-dog pharmacokinetic study reported short elimination half-lives, high systemic clearance, and very low oral bioavailability for beta-caryophyllene alcohol across the tested formulations.
This experimental finding does not establish benefit, dose or safety in people using this blend.
The same study found that beta-glucuronidase treatment increased measured exposure by 24.7-fold in rats and 2.62-fold in dogs, supporting glucuronidation as an important metabolic pathway.
The same study found that beta-glucuronidase treatment increased measured exposure by 24.7-fold in rats and 2.62-fold in dogs, supporting glucuronidation as an important metabolic pathway.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A published fragrance-material review describes beta-caryophyllene alcohol as a fragrance ingredient and provides toxicologic and dermatologic review coverage, but the accessible sources reviewed here did not expose detailed endpoint tables.
A published fragrance-material review describes beta-caryophyllene alcohol as a fragrance ingredient and provides toxicologic and dermatologic review coverage, but the accessible sources reviewed here did not expose detailed endpoint tables.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The best directly located safety source is a fragrance-material review, which supports consumer-product relevance but is not the same as a constituent-specific clinical tolerability program.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
No constituent-specific IFRA dermal limit, phototoxicity warning, or human clinical safety trial was verified in the reviewed public sources for this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
glucuronidation first pass signal
The available animal pharmacokinetic study reported that beta-glucuronidase treatment markedly increased measured systemic exposure, which the authors interpreted as evidence that glucuronidation is a significant metabolic pathway and probable first-pass limitation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No human clinical studies specific to isolated beta-caryophyllene alcohol were located in the reviewed public sources.
- The accessible evidence is weighted toward identity, occurrence, fragrance use, and pharmacokinetics rather than direct mechanism or efficacy data.
- IFRA Standard 51 lists no restriction for beta-caryophyllene alcohol across all fragrance product categories; however, no isolated HRIPT/guinea-pig sensitization study specific to the alcohol (as distinct from the parent hydrocarbon or its oxide) was located to independently corroborate the sensitization endpoint.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.